Sirona Biochem Expands it Collaboration with Wanbang Biopharmaceuticals for TFC-039
Shots:
- The companies have expanded their collaboration on the use of Sirona’s SGLT2 inhibitor, TFC-039 in both animal and human health. The development of TFC-039 as a treatment for diabetes and CKD in companion animals has been discussed by Sirona with animal health companies
- In 2014, Wanbang signed a license agreement with Sirona for TFC-039 where Wanbang got the rights to develop the compound as a diabetes treatment in China and Sirona retained the global rights
- The companies focus to produce preclinical data, multiple clinical studies, and advancing towards manufacturing development & continues its collaboration with SGLT2 inhibitor along with antiviral and anti-aging projects in 2023
Ref: PRNewswire | Image: Sirona Biochem
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
